Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)
First-in-class antibody MTX-463 targets WISP-1, a secreted matricellular protein implicated in fibrosis progression Global study rapidly enrolled 168 patients across 70+ sites spanning North and South America, Europe and Australia BOSTON, Oct. 7, 2026 /PRNewswire/ -- Mediar Therapeutics,...
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


